Kopra Bio YC 申请
Kopra Bio 在 Summer 2024 批次的 Y Combinator 中作为一家 Healthcare 公司进行过。以下是：公司做什么、谁创立了它，以及其 YC 申请，按照真实 YC 表格逐题重建。
- YC 批次
- Summer 2024
- 行业
- HealthcareTherapeutics
- 团队规模
- 2
- 状态
- Active
- 已发布
- 2024
创始人
Alexander HaddadFounder
Kopra Bio 做什么
Kopra Bio makes genetically engineered viruses that teach your immune system to kill cancer using tech we developed at UCSF. We’re making the next Keytruda ($25B/yr cancer drug blockbuster) starting with the most aggressive form of brain cancer, glioblastoma. In the most challenging brain cancer model, we improve survival from 0% with the current FDA approved treatment to 90% with our treatment.
Kopra Bio 的 YC 申请，重建版
Y Combinator 申请
Kopra Bio，Summer 2024 期。来自公开数据的真实申请问题解答。
- Founders2
- Company7
- Progress7
- Idea4
- Equity3
- Curious2
- Batch Preference1
Company
Kopra Bio
Viruses engineered to train the immune system
We engineer viruses that teach a patient's immune system to recognize and destroy cancer cells. Our product targets glioblastoma, improving survival rates dramatically compared to current FDA-approved treatments. We built this using technology developed at UCSF to make immunotherapy more effective against aggressive brain cancer.
We live in San Francisco and plan to base Kopra Bio here after YC.
San Francisco is where we are rooted professionally and technically, with access to top biotech talent and where we can quickly iterate with collaborators and clinicians.
21 更多回答 在完整申请中
Founders, Progress, Idea, Equity, Curious, Batch Preference 包含在完整版中。创建免费账户即可在 YC Insights 中打开，紧邻每个其他 YC 批次。
常见问题解答
这是 Kopra Bio 的真实 YC 申请吗？
不是。Y Combinator 对提交的申请保密。这是重建版：使用 Kopra Bio 的公开数据（发布笔记、创始人背景、产品描述）回答真实的 YC 表格问题。它展示了像 Kopra Bio 这样的公司会如何向 YC 自我介绍，而不是他们提交的文本。
Kopra Bio 是哪个 YC 批次的？
Kopra Bio 是 Y Combinator Summer 2024 批次的成员。
谁创立了 Kopra Bio？
Kopra Bio 由 Alexander Haddad 创立。
Kopra Bio 做什么？
Genetically engineered viruses that teach your immune system to kill…
如何阅读完整的重建申请？
创建免费的 Round Funded 账户。YC Insights 中包含 Kopra Bio 的完整 26 个问题的版本，以及其他所有 YC 批次的公司信息。
更多 YC 初创公司，例如 Kopra Bio
